Adams Respiratory Therapeutics Report issue

Contributed to NME For profit Phase 2 Phase 4
Founded: Chester NJ United States (1997)
Status: Acquired by Reckitt Benckiser Pharmaceutical (2007)

Organization Overview

First Clinical Trial
2006
NCT00338507
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (1)

guaifenesin (NDA)

Drugs in Phase 4 Trials (1)

guaifenesin (1 trial)

Drugs in Phase 2 Trials (1)

erdosteine (1 trial)

Indications

Approved Indications


 

Common Cold

Cough

Sinusitis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bronchitis (Phase 4)

Bronchitis, Chronic (Phase 2)

Infections (Phase 4)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Respiratory Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2